SeaStar Medical Holding Beheer

Beheer criteriumcontroles 3/4

De CEO SeaStar Medical Holding is Eric Schlorff, benoemd in Jul2019, heeft een ambtstermijn van 5.33 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 637.96K, bestaande uit 65.8% salaris en 34.2% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.12% van de aandelen van het bedrijf, ter waarde $ 100.21K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.3 jaar en 0.9 jaar.

Belangrijke informatie

Eric Schlorff

Algemeen directeur

US$638.0k

Totale compensatie

Percentage CEO-salaris	65.8%
Dienstverband CEO	5.3yrs
Eigendom CEO	1.1%
Management gemiddelde ambtstermijn	2.3yrs
Gemiddelde ambtstermijn bestuur	less than a year

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Eric Schlorff's beloning veranderd ten opzichte van SeaStar Medical Holding's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$30m
Jun 30 2024	n/a	n/a	-US$33m
Mar 31 2024	n/a	n/a	-US$32m
Dec 31 2023	US$638k	US$420k	-US$26m
Sep 30 2023	n/a	n/a	-US$25m
Jun 30 2023	n/a	n/a	-US$20m
Mar 31 2023	n/a	n/a	-US$18m
Dec 31 2022	US$2m	US$320k	-US$12m
Sep 30 2022	n/a	n/a	-US$5m
Jun 30 2022	n/a	n/a	-US$4m
Mar 31 2022	n/a	n/a	-US$5m
Dec 31 2021	US$323k	US$300k	-US$5m

Compensatie versus markt: De totale vergoeding ($USD 637.96K ) Eric } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 649.63K ).

Compensatie versus inkomsten: De vergoeding van Eric is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Eric Schlorff (51 yo)

5.3yrs

Tenure

US$637,960

Compensatie

Mr. Eric Schlorff serves as Chief Executive Officer and Executive Director of SeaStar Medical Holding Corporation since July 2019 and serves as its President. He served as Chief Operating Officer at LMF Ac...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Eric Schlorff	CEO, President & Executive Director	5.3yrs	US$637.96k	1.12% $ 100.2k
Kevin Chung	Chief Medical Officer	2.3yrs	US$495.31k	0.31% $ 28.1k
H. Humes	Co-Founder and Managing Director	29.8yrs	US$205.93k	geen gegevens
David Green	Chief Financial Officer	less than a year	geen gegevens	0.24% $ 21.2k
Tom Mullen	Vice President of Operations & Product Development	2.8yrs	geen gegevens	geen gegevens
Tim Varacek	Senior VP of Commercial & Business Operations	less than a year	geen gegevens	geen gegevens
Sai Iyer	Senior Vice President of Medical Affairs & Research	less than a year	geen gegevens	geen gegevens

2.3yrs

Gemiddelde duur

51yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ICU wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.3 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Eric Schlorff	CEO, President & Executive Director	5.3yrs	US$637.96k	1.12% $ 100.2k
Glenn Chertow	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Ravindra Mehta	Member of Medical Advisory Board	no data	geen gegevens	geen gegevens
Kenneth Van Heel	Independent Director	3.8yrs	US$88.16k	0.055% $ 4.9k
Richard Barnett	Independent Chairman	3.8yrs	US$126.16k	0.079% $ 7.1k
Allan Collins	Independent Director	3.8yrs	US$80.16k	0.050% $ 4.5k
David Askenazi	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Ayse Akcan-Arikan	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Sean Bagshaw	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Rajit Basu	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
Andriy Batchinsky	Member of Scientific Advisory Board	less than a year	geen gegevens	geen gegevens
John Neuman	Director	less than a year	geen gegevens	geen gegevens

0.9yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ICU wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.9 jaar), wat duidt op een nieuw bestuur.

SeaStar Medical Holding Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

High number of new and inexperienced directors

SeaStar Medical Holding Corporation Announces Board Changes

SeaStar Medical Holding Corporation Approves Class II Director Appointments

SeaStar Medical Holding Corporation, Annual General Meeting, Jun 04, 2024

SeaStar Medical Holding Corporation Announces Chief Financial Officer Changes

SeaStar Medical Forms Scientific Advisory Board of Pediatric and Adult Clinical Experts

Recent updates

FDA Grants Breakthrough Device Designation for Seastar Medical’S Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis

SeaStar Medical Holding Corporation Announces Record Monthly Enrollment Achieve in It's Pivotal Adult AKI Trial

Seastar Medical Holding Corporation Enters into Confidential Settlement Agreement and Release with Nuwellis

Seastar Medical Holding Corporation Announces Enrollment in Its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $25 million.

Levi & Korsinsky, LLP Notifies Investors in Seastar Medical Holding Corporation of A Class Action Securities Lawsuit

SeaStar Medical Holding Corporation Announces First Pediatric Patient Treated in A Commercial Setting with FDA-Approved QUELIMMUNE Therapeutic Device

SeaStar Medical Holding Corporation has completed a Follow-on Equity Offering in the amount of $10.000007 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $10.000007 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $10.000007 million.

The Schall Law Firm Reminds Class Action Lawsuit Against SeaStar Medical Holding Corporation

SeaStar Medical Holding Provides Notice to the Nasdaq Stock Market Regarding its Possible Violation of Nasdaq Listing Rule 5635(d)(2)

SeaStar Medical Holding Provides Notice to the Nasdaq Stock Market Regarding its Possible Violation of Nasdaq Listing Rule 5635(d)(2)

SeaStar Medical Holding Corporation Finalizes FDA Labeling Requirement for QUELIMMUNE, Paving the Way for First Commercial Sales as Humanitarian Use Device

High number of new and inexperienced directors

SeaStar Medical Holding Announces Compliance Update with Nasdaq Listing Rule 5550(b)(2) and Nasdaq Listing Rule 5550(a)(2)

SeaStar Medical Holding Corporation Announces Board Changes

SeaStar Medical Holding Corporation Approves Class II Director Appointments

SeaStar Medical Holding Corporation, Annual General Meeting, Jun 04, 2024

SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

SeaStar Medical Announces $3.6 Million NIH Grant Award to Study the Selective Cytopheretic Device in Adult Patients with Severe Chronic Heart Failure

SeaStar Medical Holding Corporation announced delayed annual 10-K filing

Seastar Medical Provides Updates on Enrollment of Adult Pivotal Clinical Study and Commercial Launch of Quelimmune, FDA-Approved in Pediatric Patients

FDA Grants Humanitarian Device Exemption Approval to Seastar Medical’S Selective Cytopheretic Device for Pediatric Acute Kidney Injury

SeaStar Medical Holding Receives Notification from the Nasdaq Listing Qualifications Department Regarding the Company Regains Compliance with the Market Value Rule

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation has filed a Follow-on Equity Offering in the amount of $9 million.

SeaStar Medical Holding Corporation Announces Chief Financial Officer Changes

SeaStar Medical Holding Receives Non-Compliance Notice from Nasdaq

SeaStar Medical Holding Corporation Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

SeaStar Medical Holding Corporation Updates Subject Enrollment in its Pivotal Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

SeaStar Medical Holding Receives Notification from the Nasdaq Listing Qualifications Department of the Nasdaq Stock Market

SeaStar Medical Forms Scientific Advisory Board of Pediatric and Adult Clinical Experts

New major risk - Shareholder dilution

U.S. Food and Drug Administration Issues Approvable Letter for SeaStar Medical Holding Corporation's Selective Cytopheretic Device for Pediatric Patients

FDA Grants SeaStar Medical’s Selective Cytopheretic Device Breakthrough Device Designation for Hepatorenal Syndrome

SeaStar Medical Holding Corporation Announces Publication of Case Series of Three Critically Ill Children with Acute Kidney Injury Safely Treated with it's Selective Cytopheretic Device

SeaStar Medical Holding Corporation Enrolls First Patient in NEUTRALIZE-AKI Pivotal Clinical Trial with the Selective Cytopheretic Device in Adults with Acute Kidney Injury

Seastar Medical Holding Receives Nasdaq Staff Deficiency Letter Regarding Non-Compliance with Market Value of Listed Securities Requirements

SeaStar Medical Holding Corporation, Annual General Meeting, Jun 28, 2023

SeaStar Medical Holding Corporation Provides Regulatory Update Related to HDE Application for Pediatric Selective Cytopheretic Device

SeaStar Medical Announces Details of the Selective Cytopheretic Device Pivotal Study in Critically ill Adults with Acute Kidney Injury

Seastar Medical Receives FDA Approval to Begin Study with Selective Cytopheretic Device to Reduce Hyperinflammation in Adults with Acute Kidney Injury

SeaStar Medical Holding Corporation Submits Investigational Device Exemption Application to FDA to Study a Novel Therapy to Reduce Hyperinflammation in Adult Acute Kidney Injury Patients

High number of new directors

Seastar Medical Appoints Rick Barnett as Chairman of the Board of Directors

No independent directors

SeaStar Medical Announces Positive Interim Safety Findings from Ongoing Study Evaluating the Selective Cytopheretic Device (SCD) in Children

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd